Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | HPGD | P15428 | 7/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14269551 | 0.89 | ALDH1A1 (0.55) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL4884293 | 0.88 | KDM4E (0.57) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL30474792 | 0.83 | CA1 (0.59) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL5326250 | 0.83 | CA1 (0.59) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL1433137 | 0.82 | ALDH1A1 (0.57) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL18775430 | 0.82 | PRKCI (0.45) | ALDH1A1MAPTHPGDNPC1RAB9A | |
| SCHEMBL4035803 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL17055696 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL28555408 | 0.80 | KDM4E (0.48) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL25224061 | 0.79 | CA1 (0.59) | KDM4EALDH1A1MAPTHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039625-A1 | Screening Methods | LAUTENS MARK | 2008-02-14 | — | — | US | claimed |
| EP-1817283-A1 | 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | Lautens, Mark (CA) | 2007-08-15 | — | — | EP | claimed |
| WO-2006047888-A1 | 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2006-05-11 | — | — | WO | claimed |
| US-20170114019-A1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | HARO PHARMACEUTICAL INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114019-A1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | HARO PHARMACEUTICAL INC. | 2017-04-27 | — | — | US | disclosed |
| US-8410144-B2 | Substituted indolo-pyridinone compounds | ARQULE, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410144-B2 | Substituted indolo-pyridinone compounds | ARQULE, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410144-B2 | Substituted indolo-pyridinone compounds | ARQULE, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2414344-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ArQule, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114896-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114896-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249127-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249127-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20080039625-A1 | Screening Methods | LAUTENS MARK | 2008-02-14 | — | — | US | disclosed |
| US-20080039625-A1 | Screening Methods | LAUTENS MARK | 2008-02-14 | — | — | US | disclosed |
| US-20080039625-A1 | Screening Methods | LAUTENS MARK | 2008-02-14 | — | — | US | disclosed |
| WO-2007134421-A1 | 2-VINYL INDOLES, PYRIDO AND AZEPINO INDOLE DERIVATIVES, 2-ALKYNYL INDOLES, 2-ALKYNYL BENZO[b]FURANS, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007134421-A1 | 2-VINYL INDOLES, PYRIDO AND AZEPINO INDOLE DERIVATIVES, 2-ALKYNYL INDOLES, 2-ALKYNYL BENZO[b]FURANS, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2007-11-29 | — | — | WO | disclosed |
| EP-1817283-A1 | 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | Lautens, Mark (CA) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006047888-A1 | 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249127-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | MKI67, CCNI, CDK4 | KDM4E 1330/4885ALDH1A1 686/4885MAPT 1367/4885 |
| US-20080039625-A1 | Screening Methods | CBR3, ZKSCAN2, CRBN | KDM4E 3829/4885ALDH1A1 2175/4885MAPT 4661/4885 |
| US-20170114019-A1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | CKMT1A; CKMT1B, MYLK2, CPT1B | KDM4E 729/4885ALDH1A1 2397/4885MAPT 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.